McCormick Q2 Earnings Beat Estimates

McCormick Q2 earnings beat estimates as sales and adjusted profit rose, with margin gains from pricing, the Mexico deal and a tariff refund bolstering shares.

June 25, 2026·2 min read
View all news articles
Flat vector cover showing a seasoning jar with an expanding rim to symbolize margin expansion tied to McCormick Q2 earnings.

KEY TAKEAWAYS

  • Reported Q2 net sales $1.94B and adjusted EPS $0.80.
  • Gross margin widened 270 bps to 40.2% from pricing, the Mexico acquisition and a $28 million tariff refund.
  • Reaffirmed fiscal 2026 guidance with adjusted EPS $3.05-$3.13.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

McCormick & Company, Incorporated (MKC) reported fiscal second-quarter 2026 results on June 25, beating estimates on sales and adjusted profit. The company reaffirmed its fiscal 2026 guidance, citing margin gains from pricing, the McCormick de Mexico acquisition, and an International Emergency Economic Powers Act (IEEPA) tariff refund.

Quarter Results and Margin Expansion

For the quarter ended May 31, McCormick reported net sales of $1.94 billion, up 16.7% year over year. Adjusted diluted earnings per share (EPS) rose to $0.80 from $0.69 a year earlier, while adjusted operating income increased to $336 million from $259 million. GAAP diluted EPS declined to $0.56 from $0.65. Gross margin expanded 270 basis points to 40.2%, and organic sales grew roughly 1.7% to 2.0%, primarily driven by pricing.

Management attributed the margin expansion to cost savings from its CCI productivity program, the McCormick de Mexico acquisition, pricing, and an IEEPA tariff refund of about $28 million.

Guidance and Strategic Outlook

McCormick reaffirmed its fiscal 2026 guidance, projecting net sales growth of 13% to 17%, organic sales growth of 1% to 3%, adjusted operating income growth of 16% to 20%, and adjusted diluted EPS between $3.05 and $3.13. Management said these targets reflect ongoing benefits from the McCormick de Mexico acquisition, pricing, and productivity initiatives.

The company continued integration planning for the previously announced Unilever Foods combination. Market commentary noted the earnings beat was supported by stronger demand for spices and seasonings as consumers cooked more at home amid economic uncertainty. The reaffirmed guidance signals management’s expectation that these drivers will sustain fiscal 2026 results.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

Read other top news stories

MSTR Stock Under Pressure After Bitcoin Weakness

MSTR Stock Under Pressure After Bitcoin Weakness

MSTR stock slid after Bitcoin losses and recent filings raised convertible debt and liquidity questions that could heighten funding and hedging pressure.

Palantir Stock Near 52-Week Low Amid Contract Wins

Palantir Stock Near 52-Week Low Amid Contract Wins

Palantir stock slid toward a 52-week low after a multiday selloff even as it won the U.S. Army NGC2 data layer role, sharpening trader valuation tradeoffs

Fed Stress Test 2026 Leaves Capital Rules Unchanged

Fed Stress Test 2026 Leaves Capital Rules Unchanged

Fed Stress Test 2026 found banks stayed above minimum CET1; the Fed said results won't change capital requirements until 2027, easing buyback constraints.

BlackBerry Earnings Lift 2027 Outlook

BlackBerry Earnings Lift 2027 Outlook

BlackBerry earnings showed stronger Q1 revenue and cash flow and the company raised fiscal-2027 revenue guidance, supporting buybacks and positioning.

Darden Earnings Beat, Dividend Raised, New Buyback

Darden Earnings Beat, Dividend Raised, New Buyback

Darden earnings beat as sales rose; board hiked dividend to $1.62 and authorized a $1.5 billion buyback, putting trader focus on capital returns.

Bayer Roundup Ruling Eases Legal Overhang

Bayer Roundup Ruling Eases Legal Overhang

Bayer Roundup ruling preempts state failure-to-warn claims under FIFRA, sharply narrowing Bayer's litigation overhang and easing investor legal-risk premium.